Related Experiment Video
Updated: Jun 26, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
[Progress in the new nonnucleoside anti-HIV reverse transcriptase inhibitor-DCK]
1Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Abstract:
3',4'-Di-O-(S)-comphanoyl-(+)-cis-khellactone (DCK) is a synthetic khellactone ester that exhibits potent anti-HIV activity with a mechanism distinct from clinically used anti-HIV agents. Several series of DCK analoges have been synthesized and evaluated for inhibitory effects against HIV. This review article describes recent progress in the discovery, structural modification, and structure-activity relationship studies of potent anti-HIV DCK derivatives.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Inhibition of CDK Activity

